RemeGen Co Ltd
SHH: 688331.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jianmin Fang
- Employees
- 2,999
- Headquarters
- Yantai, China
- IPO year
- 2022
- Market cap
- CN¥68.6B
- Website
- https://www.remegen.com
Loading 688331…
Loading profile data…Frequently asked questions about 688331
What does RemeGen Co Ltd (688331.SS) do?
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythemato...
Where does 688331.SS trade?
RemeGen Co Ltd (688331.SS) trades on the Shanghai Stock Exchange.
What sector is 688331.SS in?
RemeGen Co Ltd (688331.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RemeGen Co Ltd?
Jianmin Fang is the chief executive officer of RemeGen Co Ltd (688331.SS).
Where is RemeGen Co Ltd headquartered?
RemeGen Co Ltd is headquartered in China.
Does 688331.SS pay a dividend?
RemeGen Co Ltd (688331.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 688331.SS go public?
RemeGen Co Ltd (688331.SS) completed its initial public offering in 2022.